Rhythm Pharmaceuticals (RYTM)

Executive Summary

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing precision medicines for rare genetic diseases of obesity. Its lead product, IMCIVREE® (setmelanotide), is approved in the U.S. for chronic weight management in patients with POMC, PCSK1, LEPR deficiency, and Bardet-Biedl syndrome. The company has a robust pipeline targeting additional rare obesity disorders, including hypothalamic obesity and Prader-Willi syndrome. As a public company (NASDAQ: RYTM), Rhythm has established a global commercial presence and continues to expand its portfolio through internal development and potential partnerships. The company's mission centers on transforming the lives of patients with rare neuroendocrine diseases by advancing targeted therapies that address the root causes of these conditions. Rhythm Pharmaceuticals is poised for several near-term catalysts that could drive significant value. The company is advancing a Phase 3 trial of setmelanotide in hypothalamic obesity, with top-line data expected in the second half of 2026. Additionally, its early-stage pipeline includes RM-718, a novel MC4R agonist in Phase 1/2 for hypothalamic obesity and Prader-Willi syndrome, with initial data anticipated in 2026. Beyond pipeline progress, Rhythm may also pursue label expansions for IMCIVREE based on completed trials, such as its Phase 3 study in Alström syndrome. With a strong commercial foundation and multiple value-driving milestones, Rhythm Pharmaceuticals represents a compelling opportunity in the rare disease space.

Upcoming Catalysts (preview)

• H2 2026Phase 3 top-line data for setmelanotide in hypothalamic obesity70% success
• 2026Initial Phase 1/2 data for RM-718 in hypothalamic obesity and Prader-Willi syndrome60% success
• 2026Potential FDA approval for setmelanotide in Alström syndrome80% success